Ionis Pharmaceuticals (IONS) Competitors $42.70 -0.54 (-1.24%) Closing price 03:59 PM EasternExtended Trading$42.70 -0.01 (-0.02%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, INCY, UTHR, NBIX, BMRN, EXEL, MDGL, HALO, EXAS, and RGENShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Exact Sciences (EXAS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Halozyme Therapeutics Exact Sciences Repligen Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings. Does the media prefer BIIB or IONS? In the previous week, Biogen had 11 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 33 mentions for Biogen and 22 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 1.11 beat Ionis Pharmaceuticals' score of 0.96 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 24 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, BIIB or IONS? Biogen has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Which has stronger earnings & valuation, BIIB or IONS? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$10.00B2.04$1.63B$10.4613.30Ionis Pharmaceuticals$705M9.65-$453.90M-$1.84-23.21 Is BIIB or IONS more profitable? Biogen has a net margin of 15.31% compared to Ionis Pharmaceuticals' net margin of -28.25%. Biogen's return on equity of 13.85% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Ionis Pharmaceuticals -28.25%-45.29%-8.99% Do analysts prefer BIIB or IONS? Biogen presently has a consensus price target of $185.74, suggesting a potential upside of 33.46%. Ionis Pharmaceuticals has a consensus price target of $60.85, suggesting a potential upside of 42.49%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Ionis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86 Do insiders & institutionals hold more shares of BIIB or IONS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryBiogen beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.81B$2.81B$5.83B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-23.2122.6631.1625.99Price / Sales9.65760.87474.86122.97Price / CashN/A173.2237.1558.38Price / Book10.785.879.116.38Net Income-$453.90M$31.83M$3.26B$265.56M7 Day Performance-2.46%1.78%2.06%1.89%1 Month Performance1.79%4.33%5.08%1.23%1 Year Performance-10.17%11.50%31.26%21.10% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.6315 of 5 stars$42.70-1.2%$60.85+42.5%-10.3%$6.81B$705M-23.211,069Trending NewsAnalyst ForecastInsider TradeBIIBBiogen4.8527 of 5 stars$128.00-2.0%$185.63+45.0%-32.5%$18.77B$9.68B12.247,605Positive NewsINCYIncyte4.7354 of 5 stars$79.19+1.0%$81.20+2.5%+34.9%$15.46B$4.24B18.002,617Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.9113 of 5 stars$300.43-0.4%$379.69+26.4%-11.6%$13.55B$2.88B11.731,305Positive NewsNBIXNeurocrine Biosciences4.867 of 5 stars$123.98-0.8%$160.90+29.8%-10.3%$12.30B$2.51B36.681,800Positive NewsBMRNBioMarin Pharmaceutical4.9964 of 5 stars$56.80-0.9%$93.17+64.0%-37.3%$10.91B$2.85B16.853,040Positive NewsEXELExelixis4.9113 of 5 stars$37.41-0.8%$44.44+18.8%+47.0%$10.07B$2.17B17.991,147Trending NewsAnalyst RevisionMDGLMadrigal Pharmaceuticals3.5649 of 5 stars$349.50+1.1%$430.43+23.2%+58.9%$7.76B$180.13M-27.2090News CoverageAnalyst ForecastInsider TradeAnalyst RevisionHALOHalozyme Therapeutics4.7103 of 5 stars$62.92+0.0%$66.56+5.8%+15.2%$7.75B$1.02B14.40390News CoveragePositive NewsEXASExact Sciences4.9027 of 5 stars$40.91-0.2%$68.14+66.6%-21.8%$7.75B$2.76B-7.537,000RGENRepligen4.8627 of 5 stars$111.88+0.4%$169.45+51.5%-21.8%$6.29B$673.96M-447.501,778News CoveragePositive News Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors BMRN Competitors EXEL Competitors MDGL Competitors HALO Competitors EXAS Competitors RGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access